Role of beta-3 adrenergic receptor polymorphism TRY64ARG in heart failure

Abstract Introduction The TRY64ARG polymorphism of the beta-3 adrenergic receptor has been associated with the onset and maintenance of hypertension, diabetes and obesity, its role in heart failure has not been studied. Objectives To examine the role of the TRY64ARG beta-3 adrenergic receptor in the improvement of left ventricular ejection fraction (LVEF) in patients with Heart Failure due to ischemic heart disease. Methods This study is a retrospective analysis based on a 5-year follow-up of patients with heart failure with decreased LVEF due to ischemic heart disease. Results We studied a sample of 338 patients with decreased LVEF collected from our Genetic database during the period of time from January 2012 to December 2016. In the scrutiny 26 patients did not have complete data for analysis, resulting in a final sample of 312 patients with a minimum follow-up of 5 years. The mean age was 58.9 years (SD 14), 72% of the population were men (n = 244), the frequency of hypertension was 168 (53.85%), diabetes 119 (38.14%), obesity (18.27%). The definition of LVEF improvement was defined as an incremental in more than 15%. There was no statistical difference in the medical treatment and revascularization methods. Patients with the TRY64ARG β3 adrenergic polymorphism present less improvement in the LVEF (42% vs 58%, p< 0.001). Conclusions The expression of the TRY64ARG polymorphism of the beta-3 adrenergic receptor in patients with HF and low LVEF is related to a lack of incremental LVEF at 5 years.